Hydrafacial Results Presentation Deck slide image

Hydrafacial Results Presentation Deck

Q3 2022 balance sheet highlights Cash and Cash Equivalents Warrants Convertible Debt Revolving Credit Facility Shares Outstanding 31 1. As of 09/30/22. Approximately $684.2 million cash and cash equivalents on balance sheet Approximately 7.0 million Private Warrants outstanding¹ $750.0 million 1.25% convertible notes due 2026 Use of proceeds: capped call transaction, potential future acquisitions, working capital expenditures, and general corporate purposes Conversion price of $31.76; capped call agreement provides dilution protection up to $47.94 $50.0 million Senior Secured Credit Facility remains undrawn; current undrawn commitment fee of 25 bps Allows flexibility for future M&A; ex-US operations unencumbered; convertible debt excluded from covenants ✦ Approximately 143.2 million current shares outstanding¹ $100 million Accelerated Share Repurchase program expected to be completed by the end of Q1 2023 Additional $100 million share buyback authorization remaining BEAUTYHEALTH™
View entire presentation